

Press Release



Joint development and option agreement with Renaissance Inc. within the therapeutic area of Gynecology

TOKYO, December 24th, 2019 - ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") has announced that it has reached an agreement with Renaissance Inc. (Head Office: Chuo-Ku, Tokyo, President: Atsushi Tanase, hereinafter "Renaissance ") regarding RS8001 (pyridoxamine) which is a product developed by Renaissance, for joint development and for an exclusive option agreement.

Renaissance and ASKA will collaborate with Tohoku University and Kinki University medical institutions to conduct Phase 2 investigator initiated clinical trials regarding RS8001.

Under this agreement, ASKA will acquire the priority negotiation rights to receive exclusive license for developing and commercializing RS8001 within Japan for the indication of Premenstrual syndrome and Premenstrual dysphoric disorder (PMS/PMDD), and Renaissance will receive an option agreement fee with the possibility of receiving future license agreement fee as well.

By utilizing Renaissance's R&D capabilities and ASKA's strengths within obstetrics and gynecology, the two companies will create innovative medications that will further contribute to the unmet needs of patients and their families.

The effect of this matter on ASKA's business for the fiscal year ending on March 2020, is minimal.

[About Renaissance]

As humanity will face major medical issues in "Aging" as well as in "Mental stress" in the near future, Renaissance will challenge these medical issues by working together with researchers and doctors both in Japan and overseas to create valuable medical innovations so that people can enjoy their health, both physically and mentally.

For more details, please visit the website <https://www.renaissance.co.jp/en/index.html>

[About ASKA Pharmaceutical Co., Ltd.]

Since its establishment in 1920, ASKA Pharmaceutical has been a specialty pharma that focuses on, and provides products related to therapeutic areas in Internal medicine, Obstetrics and gynecology, and Urology, and is expanding its lineup.

For more information, please visit <https://www.aska-pharma.co.jp/english/>

[Inquiries regarding this matter]

Renaissance: +81-3-6262-0873

ASKA Pharmaceutical: +81-3-5484-8366